<DOC>
	<DOCNO>NCT00796978</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . PURPOSE : This phase II trial study side effect trastuzumab see well work treat old woman early-stage breast cancer .</brief_summary>
	<brief_title>Trastuzumab Treating Older Women With Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate 3-year cumulative incidence cardiac event old woman HER2-positive early stage breast cancer treat adjuvant trastuzumab ( Herceptin® ) . Secondary - To evaluate 3-year cumulative incidence asymptomatic cardiac leave ventricular dysfunction patient . - To assess relation physiologic marker chronic heart failure trastuzumab-related cardiac dysfunction patient . - To assess relation pro-inflammatory cytokine trastuzumab-related cardiac dysfunction patient . - To determine effect drug health-related quality life functional , cognitive , mental status patient . - To determine 3-year disease-free survival overall survival patient . OUTLINE : This multicenter study . Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 . Treatment repeat every 3 week 52 week absence disease progression unacceptable toxicity . Blood collect every 6 week treatment . Samples assess plasma cardiac marker ( N-terminal brain natriuretic protein troponin-I ) pro-inflammatory cytokine ( interleukin-6 tumor necrosis factor-α ) . Patients complete Quality Life Quality Health Comprehensive Geriatric assessment functional , cognitive , mental status change baseline , week 26 , 52 . After completion study therapy , patient follow periodically 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Early stage disease ( T , N , M0 ) No metastatic disease Must undergone complete surgical removal invasive cancer mastectomy lumpectomy either sentinel axillary lymph node dissection within past 84 day Must receive either whole partial breast radiotherapy external beam brachytherapy completion primary surgery Unable unwilling receive chemotherapy HER2positive , define 3+ IHC HER2 gene amplification FISH Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy &gt; 6 month ANC &gt; 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin &gt; 10 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN AST ALT &lt; 2 time ULN ( unless relate primary disease ) LVEF normal Ejection fraction ≥ 50 % No active cardiac disease , include following : Prior myocardial infarction ( MI ) ( asymptomatic change suggestive old MI EKG allow ) Angina pectoris require antianginal treatment Documented CHF Cardiac arrhythmia require medication Uncontrolled hypertension ( diastolic BP &gt; 100 mm Hg systolic BP &gt; 200 mm Hg ) Clinically significant valvular abnormality pericardial effusion ( associate NYHA class IIIV symptom ) No history CHF cardiomyopathy No concurrent prior malignancy within past 5 year , except adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix No symptomatic intrinsic lung disease extensive tumor involvement lung result dyspnea rest No active infection No emotional limitation No hypersensitivity trastuzumab ( Herceptin® ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy disease No prior trastuzumab ( Herceptin® ) Adjuvant trastuzumab radiotherapy allow No concurrent therapy specifically congestive heart failure ( CHF ) No concurrent chemotherapy biologic agent Hormonal therapy patient hormone receptorpositive disease allow</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>